#monoclonalantibodies — Public Fediverse posts

Researchers identify first suite of human antibodies against measles virus

Thursday, May 14, 2026 NIH-funded study lays foundation for antibody-based measles treatment.

Colorized transmission electron micrograph of…
#NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #against #America #Antibodies #identify #measles #monoclonalantibodies #NIAID #NIH #Researchers #UnitedStatesofAmerica
https://www.newsbeep.com/us/643080/

Researchers identify first suite of human antibodies against measles virus

Thursday, May 14, 2026 NIH-funded study lays foundation for antibody-based measles treatment.

Colorized transmission electron micrograph of…
#NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #against #America #Antibodies #identify #measles #monoclonalantibodies #NIAID #NIH #Researchers #UnitedStatesofAmerica
https://www.newsbeep.com/us/643080/

https://www.europesays.com/ch/31680/ Novartis invests US$200min lacklustre Parkinson’s target #AlphaSynuclein #Arrowhead #LicenceDeal #MonoclonalAntibodies #Novartis #Parkinson'sDisease #siRNA

https://www.europesays.com/ie/317445/ Immunotherapy Blocking Microglial FcγR Prevents Neuron Loss in Parkinson’s Disease #Éire #IE #ImmuneCells #immunotherapy #Ireland #MonoclonalAntibodies #mouse #News #Parkinson'sDisease #Phagocytosis #Technology #topics #TranslationalMedicine

How I Built a Machine Learning Tool to Predict Drug Manufacturing Failures

https://kemal.yaylali.uk/from-bioreactors-to-ai-how-i-built-a-machine-learning-tool-to-predict-drug-manufacturing-failures/

From Bioreactors to AI: How I Built a Machine Learning Tool to Predict Drug Manufacturing Failures

https://kemal.yaylali.uk/from-bioreactors-to-ai-how-i-built-a-machine-learning-tool-to-predict-drug-manufacturing-failures/

From Bioreactors to AI: How I Built a Machine Learning Tool to Predict Drug Manufacturing Failures

https://kemal.yaylali.uk/from-bioreactors-to-ai-how-i-built-a-machine-learning-tool-to-predict-drug-manufacturing-failures/

🧬 One amino acid to stabilize them all — myth or molecular reality?

🔗 Single-residue engineering of lambda (λ) antibody light chains reduces conformational flexibility and enhances thermal stability. Computational and Structural Biotechnology Journal, DOI: https://doi.org/10.1016/j.csbj.2025.10.045

📚 CSBJ: https://www.csbj.org/

#MonoclonalAntibodies #mAbs #Immunology #ComputationalBiology #MolecularDynamics #Bioinformatics #ProteinStability #StructuralBiology

For my fellow allergy sufferers - this looks promising!

> That means an injection could stop all allergic reactions — not only seasonal allergies but food allergies (such as peanuts) and insect allergies for a prolonged period of time.

https://www.vox.com/health/408749/allergy-season-pollen-grass-cure-treatment

via @Vox

#allergies #pollen #ImmuneSystem #MonoclonalAntibodies

Structural Convergence and Water-Mediated Substrate Mimicry Enable Broad #Neuraminidase #Inhibition by #Human #Antibodies

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2024.11.27.625426v1?rss=1

Abstract
Influenza has been responsible for multiple global pandemics and seasonal epidemics and claimed millions of lives. The imminent threat of a panzootic outbreak of avian influenza H5N1 virus underscores the urgent need for pandemic preparedness and effective countermeasures, including monoclonal antibodies (mAbs). Here, we characterize human mAbs that target the highly conserved catalytic site of viral neuraminidase (NA), termed NCS mAbs, and the molecular basis of their broad specificity. Cross-reactive NA-specific B cells were isolated by using stabilized NA probes of non-circulating subtypes. We found that NCS mAbs recognized multiple NAs of influenza A as well as influenza B NAs and conferred prophylactic protections in mice against H1N1, H5N1, and influenza B viruses. Cryo-electron microscopy structures of two NCS mAbs revealed that they rely on structural mimicry of sialic acid, the substrate of NA, by coordinating not only amino acid side chains but also water molecules, enabling inhibition of NA activity across multiple influenza A and B viruses, including avian influenza H5N1 clade 2.3.4.4b viruses. Our results provide a molecular basis for the broad reactivity and inhibitory activity of NCS mAbs targeting the catalytic site of NA through substrate mimicry.

____

#aH1n1 #aH5n1 #abstract #avianInfluenza #AVIANINFLUENZA #birdFlu #h5n1 #health #influenzaB #monoclonalAntibodies #news #research #SEASONALINFLUENZA

Structural basis of broad #protection against #influenza virus by a #human #antibody targeting the #neuraminidase active site via a recurring motif in CDR H3

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2024.11.26.625467v1

Abstract
Influenza viruses evolve rapidly, driving seasonal epidemics and posing global pandemic threats. While neuraminidase (NA) has emerged as a vaccine target, shared molecular features of NA antibody responses are still not well understood. Here, we describe cryo-electron microscopy structures of the broadly protective human antibody DA03E17, which was previously identified from an H1N1-infected donor, in complex with NA from A/H1N1, A/H3N2, and B/Victoria-lineage viruses. DA03E17 targets the highly conserved NA active site using its long CDR H3, which features a DR (Asp-Arg) motif that engages catalytic residues and mimics sialic acid interactions. We further demonstrate that this motif is conserved among several NA active site-targeting antibodies, indicating a common receptor mimicry strategy. We also identified potential antibody precursors containing this DR motif in all donors of a healthy human donor BCR database, highlighting the prevalence of this motif and its potential as vaccine targeting. Our findings reveal shared molecular features in NA active site-targeting antibodies, offering insights for NA-based universal influenza vaccine design.

____

#aH3n2 #abstract #biology #h1n1pdm09 #health #immunology #influenzaA #monoclonalAntibodies #research #vaccine

Protective threshold of a potent neutralizing #Zika virus monoclonal #antibody in rhesus #macaques

Source: Journal of Virology, https://journals.asm.org/doi/full/10.1128/jvi.01429-24?af=R

ABSTRACT
Zika virus (ZIKV) is a mosquito-borne flavivirus that caused a global pandemic in 2016–2017 with continued ongoing transmission at low levels in several countries. In the absence of an approved ZIKV vaccine, neutralizing monoclonal antibodies (mAbs) provide an option for the prevention and treatment of ZIKV infection. Previous studies identified a potent neutralizing human mAb ZIKV-117 that reduced fetal infection and death in mice following ZIKV challenge. In this study, we report exquisite potency of ZIKV-117-LALA-YTE, which has been engineered to reduce Fc receptor binding and to extend half-life, in a titration study in rhesus macaques to protect against ZIKV challenge. We show complete protection at a dose of 0.016 mg/kg ZIKV-117-LALA-YTE, which resulted in median serum concentrations of 0.13 µg/mL. The high potency of this mAb supports its potential clinical development as a novel biotherapeutic intervention for ZIKV.

____

#abstract #animalModels #monoclonalAntibodies #research #zikaVirus

The developer of a biologic drug-making process with engineered plant crops is collaborating with a vertical farming company to create a network of biologics production facilities.

https://sciencebusiness.technewslit.com/?p=45058

#News #Press #Science #Business #Agriculture #Biotechnology #Collaboration #Biologics #MonoclonalAntibodies #Engineering #VerticalFarming #Tobacco #Automation #Algorithms #Italy #UK

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2024.11.08.622746v1?rss=1

Abstract
Pemivibart (Pemgarda/VYD222) was granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) on March 22, 2024, for COVID-19 pre-exposure prophylaxis in immunocompromised individuals. However, its efficacy and resistance against JN.1 sublineages have yet to be fully characterized. Here, we first assessed the neutralizing activity of Pemivibart against a panel of VSV-based pseudoviruses representing contemporary JN.1 sublineages, including XEC, the fastest-growing SARS-CoV-2 strain globally, in both Vero-E6 and Vero-E6-TMPRSS2-T2A-hACE2 (Vero-E6-TA) cells. We then engineered a replication-competent vesicular stomatitis virus with JN.1 spike (rVSVΔG-JN.1) to select for escape variants and performed structural analyses to comprehensively map Pemivibart’s escape mutations. Our results demonstrated that Pemivibart exhibited comparable neutralization patterns in both cell lines and retains broad effectiveness against SARS-CoV-2 JN.1 sublineages tested. However, its potency was remarkably reduced against KP.3.1.1 and XEC, with IC50 values of approximately 4.2 μg/mL, about 22-fold higher than that for JN.1, as well as JN.1-derived Pemivibart-escape mutants harbouring low-frequency mutations across SARS-CoV-2 strains through mutiple antibody evasion mechanisms in Vero-E6-TA cells. Collectively, our findings underscored the importance of monitoring the clinical efficacy of Pemivibart as JN.1 sublineages continue to evolve. The escape profile of Pemivibart could provide valuable insights for forecasting and optimizing its effectiveness against emerging SARS-CoV-2 variants.

____

https://etidioh.wordpress.com/2024/11/11/neutralizing-activity-and-viral-escape-of-pemivibart-by-sars-cov-2-jn1-sublineages/

#abstract #covid #COVID19 #health #monoclonalAntibodies #research #sarsCov2 #vaccine

A company formed by M.D. Anderson Cancer Center and Panacea Venture plans to develop synthetic antibodies as treatments addressing new cancer targets.

https://sciencebusiness.technewslit.com/?p=45176

#News #Press #Science #Business #Entrepreneurs #Biotechnology #StartUp #IntellectualProperty #Cancer #MonoclonalAntibodies #Tumors #Proteins #Antigens #Therapies #Treatments #VentureCapital

Disease Modifying Therapy for #Alzheimer's #Dementia

"The long-awaited era of disease-modifying therapy for Alzheimer’s disease has finally arrived and will substantially impact how the disease is perceived and managed. The drugs closest to widespread clinical implementation are #lecanemab and #donanemab—intravenous #MonoclonalAntibodies that remove β #amyloid plaques from the #brain and can slow cognitive and functional decline."
#leqembi
https://cnmri.com/2023/07/21/disease-modifying-therapy-for-alzheimers/

My latest Clinical Pipeline column for Nature Medicine: second generation anti-CD40L drugs for #MultipleSclerosis. A really cool story of deciphering the biology of adverse effects.

#Immunology #autoimmunedisease #drugdevelopment #monoclonalantibodies

https://www.nature.com/articles/d41591-023-00060-4

Quote from Dr Ruth Ann Crystal

"In this week's COVID & med newsletter:

🔎How to know if virus levels are ⬆️ or ⬇️ now that
CDC dropped reports
🧠Neuro #LongCOVID symptoms guidance
💉WHO recs new vax with XBB
🚫6 mAbs with potential to block all variants"

https://drruth.substack.com/p/covid-news-and-more-52023

#covid #health #vaccine #neurology #medical #MonoclonalAntibodies

1/n

…the new effort will focus on 3 goals: creating long-lasting #MonoclonalAntibodies, after an evolving virus rendered current treatments ineffective;accelerating development of #vaccines that produce what is known as mucosal immunity, which is thought to reduce #transmission & #infection risks; &speeding efforts to develop #PanCoronavirus vaccines to guard against #NewVariants… as well as other coronaviruses, from Middle East respiratory syndrome MERS to still-unidentified viruses in that family.

Preclinical study of anti-IL8 in endometriosis:

"We created a long-acting recycling antibody against IL-8 (AMY109) and evaluated its clinical potency. Because rodents do not produce IL-8 and do not experience menstruation, we analyzed the lesions in cynomolgus monkeys that spontaneously developed endometriosis and in a surgically induced endometriosis monkey model."
#Immunology #monoclonalantibodies #Endometriosis #inflammation

https://www.science.org/doi/10.1126/scitranslmed.abq5858

I had 114 #migraine attacks in 2022

That feels like a miracle from my perspective. For context I had 192 attacks in 2020. The difference is monthly engineered therapeutic antibody injections.

#monoclonalAntibodies #chronicillness #chronicmigraine

@kimlockhartga @Barakka @Godfrey642 @pamleo65 @Bradleycooper
All the available #MonoclonalAntibodies are ineffective against the recent #COVID variants including #XBB15. #Paxlovid still works, though we should be giving it to people for 10 days instead of 5 to reduce the frequency of rebound infections, yet another lesson that our public health infrastructure is being far too slow to learn.

#dVax #dNews #Covid #Vaccine #Jab #MonoclonalAntibodies #Regeneron #Dexamethasone
-

** URGENT from Rand Paul **
NEW COVID-19 TREATMENTS!

Recently, four DOUBLE-JABBED friends in Alaska caught COVID. They were high risk, ages 60-95! GREATLY IMPROVED by the next day!

EARLY THERAPEUTICS:
Regeneron Monoclonal Antibodies*
Dexamethasone
Zinc
Vitamins C & D
*Must be started in first 10 days!

https://www.regencov.com/hcp/dosing/dosing-administration
--
https://www.healthline.com/health-news/mon

** URGENT from Rand Paul **
NEW COVID-19 TREATMENTS!